Background: Chronic kidney disease (CKD) presents a major global health challenge due to ineffective therapies against progressive renal fibrosis. Baricitinib, a selective JAK1/JAK2 inhibitor, has ...
Twenty patients were aged 18 years or older, had chronic heart failure had chronic heart failure (New York Heart Association functional class II, III, or IV) with a decreased left ventricular ejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback